Express Pharma
NOVEMBER 12, 2024
STEERLife, and Callidus Research Laboratories have forged a strategic partnership to accelerate drug development for global markets. T his partnership also enables end-to-end drug development for highly potent APIs.
pharmaphorum
JUNE 30, 2022
Digital technologies are already helping to enable target identification, lead discovery, preclinical development, and clinical development, said Merck. The hope is that by using AI and ML capabilities, the currently unpredictable process of drug development can become much more predictable, and as a result less expensive.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 7, 2022
Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . Dr Hughes earned his MD and PhD at Yale School of Medicine.
Pharmaceutical Technology
SEPTEMBER 15, 2022
From the Human Genome Project to contemporary drug development, collaboration is critical to the life sciences. Take Charleston, South Carolina, for example, where a growing number of medical device and pharmaceutical manufacturers, research laboratories and service companies have sprung up or settled in recent years.
European Pharmaceutical Review
JUNE 28, 2024
Taly Dvorkis Fieldfisher QA/QC MICROBIOLOGY IN DEPTH FOCUS Implementing single temperature incubation Guillaume Pinon Laboratoires SERVIER Industrie Endotoxin standards: reflection and recommendation Dr Radhakrishna Tirumalai Merck Research Laboratories (MRL) Karen Zink McCullough MMI Associates, LLC Improving aseptic connections throughout the manufacturing (..)
European Pharmaceutical Review
AUGUST 12, 2024
Progress in immunotherapy drug development In June, the US Food and Drug Administration (FDA) authorised an immunotherapy combination to treat endometrial cancer. The bispecific antibody has shown potential to generate “significant and sustained reductions in B-cell populations”.
European Pharmaceutical Review
JANUARY 16, 2023
Prior to November 2013 he worked for Merck Research Laboratories in Summit, New Jersey as the Senior Principal Scientist in early phase drug development. He consults in the areas of microbial risk assessment, regulatory affairs and microbiological testing.
Expert insights. Personalized for you.
105 
Let's personalize your content